D.E. Shaw & Co
FBRX icon

D.E. Shaw & Co’s Forte Biosciences FBRX Stock Holding History

D.E. Shaw & Co’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-851
Closed -$31K – 5451
2022
Q1 		$31K Buy
+851
New +$32.2K ﹤0.01% 5260
2021
Q3 		– Sell
-1,750
Closed -$1.47M – 5033
2021
Q2 		$1.47M Buy
1,750
+752
+75% +$678K ﹤0.01% 3232
2021
Q1 		$855K Buy
+998
New +$817K ﹤0.01% 3223
2020
Q1 		– Sell
-169
Closed -$34K – 4025
2019
Q4 		$34K Sell
169
-137
-45% -$31K ﹤0.01% 3907
2019
Q3 		$76K Buy
306
+240
+364% +$364K ﹤0.01% 3711
2019
Q2 		$166K Sell
66
-279
-81% -$827K ﹤0.01% 3497
2019
Q1 		$1.41M Buy
345
+247
+252% +$954K ﹤0.01% 2392
2018
Q4 		$301K Buy
+98
New +$422K ﹤0.01% 3343

Other funds holding FBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co's FBRX Position: Q2 2022 in Review

D.E. Shaw & Co sold out of Forte Biosciences (FBRX) in Q2 2022, closing a stake of 851 shares — an estimated $31K sold.

D.E. Shaw & Co first reported a position in FBRX in Q4 2018 and held it in 8 quarters. The position peaked at $1.47M in Q2 2021. 39 funds tracked by Wall St. Rank hold FBRX as of Q2 2022.

  • D.E. Shaw & Co reported no remaining Forte Biosciences position as of Q2 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 851 Forte Biosciences shares in Q2 2022, an estimated $31K.
  • D.E. Shaw & Co first reported a position in Forte Biosciences in Q4 2018 and held it in 8 quarters.
  • D.E. Shaw & Co's Forte Biosciences position peaked at $1.47M in Q2 2021.
  • 39 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.